Free Newsletter
Microneedle tech studied for administrating flu vax
Hate needles? Researchers are looking for a way to bring pain-free flu vaccines to the public, and the results look promising. The new technology uses microneedles less than 1 millimeter long to deliver the vaccine. The needles, arranged on a Band-Aid-esque patch, dissolve into the patient's skin--and could allow persons without medical training to painlessly administer vaccines. And the researchers involved are lauding the technology as a vaccine "game changer."
In the study that was published in July 18's Nature Medicine, the scientists injected mice with the vaccine with traditional hypodermic needles or the microneedle technology, and compared them with a control group, which had received microneedle treatment without a vaccine. When exposed a month after vaccination, some mice in the control group died, while those vaccinated with either method thrived. Three months later, others in the groups were exposed to the flu, and the microneedle-treated mice did better than the hypodermic variety.
In addition to providing better protection, the patch could offer ease of use. "We envision people getting the patch in the mail or at a pharmacy and then self administering it at home," says Sean Sullivan, the study's lead author from Georgia Tech, in a statement. "Because the microneedles on the patch dissolve away into the skin, there would be no dangerous sharp needles left over."
But the new technology still has hurdles to cross, including variances in human skin unmatched in mice. "It's not uncommon for vaccines or vaccine delivery systems to look very promising in experimental animals, then fail in humans," explains Paul Offit, director of the Vaccine Education Center and chief of infectious diseases at Children's Hospital of Philadelphia to US News & World Report. "There is every reason to believe this kind of technology could be applicable to children and adults."
- see the Emory release
- here's the study
- read US News & World Report's coverage
- check out Houston Chronicle's report
Related Articles:
Computer scientist engineers tame type of live vax
Synthetic flu virus opens door to safer vaccines
Vaccine myths fuel some stubborn consumer fears
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: